Medicenna Therapeutics Eulerpool Vijesti

Medicenna Therapeutics Aktie News

Medicenna Therapeutics prate mnogi novinari i investitori širom svijeta. Najnovije Medicenna Therapeutics vijesti prikupljamo ovdje.

• 30. travnja ·

  Yahoo
  Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
• 1. travnja ·

  Yahoo
  Medicenna to Present at Jones Healthcare and Technology Innovation Conference
• 25. veljače ·

  Yahoo
  Medicenna Says New Data Shows MDNA11 Ability to Promote Anti-tumor Response
• 13. veljače ·

  Yahoo
  Medicenna Therapeutics up 12% Following Third-Quarter Results
• 13. veljače ·

  Yahoo
  Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
• 13. prosinca ·

  Yahoo
  Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
• 5. prosinca ·

  Yahoo
  Medicenna Reports Updated Data From ABILITY-1 Trial
• 5. prosinca ·

  Yahoo
  Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
• 27. studenoga ·

  Yahoo
  Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
• 25. studenoga ·

  Yahoo
  Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)